SPAC deal touch­es down for mi­cro­cap biotech armed with a PhII, for­mer Pfiz­er mon­o­clon­al an­ti­body

While SPACs have been go­ing slow af­ter the mar­ket’s per­for­mance so far, it hasn’t kept every­one away from deal­mak­ing and merg­ers.

A SPAC go­ing by JATT Ac­qui­si­tion Corp an­nounced Fri­day that it en­tered an agree­ment to com­bine with tiny biotech Zu­ra Bio Lim­it­ed, with plans to close the merg­er some­time be­fore the end of the year, ten­ta­tive­ly in Q4. Af­ter that is done, the com­pa­nies claim the com­bined en­ti­ty will be val­ued at around $215 mil­lion, re­tain the name Zu­ra Bio Lim­it­ed and list its shares on Nas­daq un­der the tick­er $ZU­RA.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER